Stay updated on Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial
Sign up to get notified when there's something new on the Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial page.

Latest updates to the Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. No visible changes to study details or page content.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision: v3.4.1 replaces Revision: v3.4.0 as a minor metadata update; this does not alter page content or user interactions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check62 days agoChange DetectedLocations have been expanded to include numerous U.S. states and international sites (Madrid, Greater London), and the revision is updated to v3.3.3.SummaryDifference1%

- Check91 days agoChange DetectedPublications section text updated to say publications are automatically filled from PubMed and may not be about the study, with a revision tag showing v3.3.2. The previous wording implying PubMed sources was replaced.SummaryDifference0.0%

- Check99 days agoChange DetectedThe page removed a government funding status notice about potential delays in updates and operating status, which previously advised users about where to check for updates (e.g., opm.gov). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial page.